Roche News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

19.11.21	European Commission approves Roche’s Gavreto (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (GlobeNewswire)
18.11.21	Roche launches cobas 5800, a new molecular diagnostics system to expand access to testing and improve patient care (GlobeNewswire)
15.11.21	Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year running (GlobeNewswire)
15.11.21	Roche zum dreizehnten Mal in Folge als eines der drei nachhaltigsten Gesundheitsunternehmen im Dow Jones Sustainability Index ausgezeichnet (GlobeNewswire)
12.11.21	Ronapreve approved by European Commission to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
11.11.21	CHMP recommends EU approval of Ronapreve to treat non-hospitalised COVID-19 patients and for prophylaxis of the disease (GlobeNewswire)
04.11.21	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche kündigt den Rückkauf der Beteiligung von Novartis an Roche an (GlobeNewswire)
04.11.21	[Ad hoc announcement pursuant to Art. 53 LR] Roche announces the repurchase of the equity stake held by Novartis in Roche (GlobeNewswire)
29.10.21	IMPACT trial data shows clear benefit in using Roche's CINtec PLUS Cytology test for women who are at higher risk of developing cervical cancer (GlobeNewswire)
25.10.21	Roche launches comprehensive genomic profiling kit to expand access to personalised cancer research (GlobeNewswire)
22.10.21	FDA approves Roche’s Susvimo, a first-of-its-kind therapeutic approach for neovascular or “wet” age-related macular degeneration (nAMD) (GlobeNewswire)
22.10.21	Roche’s VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to identify certain non-small cell lung cancer patients eligible for Tecentriq® (atezolizumab) (GlobeNewswire)
20.10.21	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit starkem Wachstum in den ersten neun Monaten 2021 – Ausblick für das Gesamtjahr erhöht (GlobeNewswire)
15.10.21	US FDA approves Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer (GlobeNewswire)
15.10.21	Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care (GlobeNewswire)
14.10.21	New four-year data show Roche's ENSPRYNG significantly reduces debilitating relapses in people with neuromyelitis optica spectrum disorder (GlobeNewswire)
14.10.21	Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma (GlobeNewswire)
13.10.21	Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression i (GlobeNewswire)
08.10.21	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designation in Alzheimer’s disease (GlobeNewswire)
05.10.21	Roche to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis optica spectrum disorder at ECTRIMS 2021 (GlobeNewswire)
30.09.21	Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantly reduces viral load within seven days of treatment in patients hospitalised with COVID-19 (GlobeNewswire)
24.09.21	Roche presents new data at World Muscle Society (WMS) 2021 highlighting new advances for people living with rare neuromuscular disorders (GlobeNewswire)
22.09.21	Roche launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to help identify multiple pathogens with overlapping symptoms in patients (GlobeNewswire)
20.09.21	New Phase III data support the benefit of Roche’s Tecentriq in early-stage lung cancer (GlobeNewswire)
17.09.21	Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer (GlobeNewswire)
15.09.21	Roche opens access to pathology imaging tools to improve patient care (GlobeNewswire)
09.09.21	Roche signs definitive share purchase agreement with long-term partner TIB Molbiol to expand PCR-test portfolio in the fight against new infectious diseases (GlobeNewswire)
07.09.21	Roche to present data from industry leading portfolio at ESMO 2021 showing significant progress in early stage and uncommon cancers (GlobeNewswire)
27.08.21	Roche provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-negative breast cancer (GlobeNewswire)
18.08.21	Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy (GlobeNewswire)
09.08.21	[Ad hoc announcement pursuant to Art. 53 LR] Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years to significantly improve outcomes in previously untreated aggressive form (GlobeNewswire)
03.08.21	US FDA grants Priority Review to Roche’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer (GlobeNewswire)
29.07.21	FDA accepts application for Roche’s faricimab for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) (GlobeNewswire)
29.07.21	Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine shows significant improvement in survival and motor milestones in babies with Type 1 spinal muscular atrophy (SMA) (GlobeNewswire)
22.07.21	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good half-year results (GlobeNewswire)
22.07.21	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche mit guten Halbjahresergebnissen (GlobeNewswire)
21.07.21	FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (GlobeNewswire)
20.07.21	Japan becomes first country to approve Ronapreve (casirivimab and imdevimab) for the treatment of mild to moderate COVID-19 (GlobeNewswire)
19.07.21	New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A (GlobeNewswire)
09.07.21	WHO guidelines now include Roche’s diagnostic tests in expanded effort to eliminate tuberculosis by providing patients greater access to timely diagnosis (GlobeNewswire)
02.07.21	Roche to present new data at the ISTH 2021 Congress highlighting long-standing commitment to advancing haemophilia A standard of care (GlobeNewswire)
28.06.21	Roche’s ENSPRYNG approved by European Commission as first and only at-home subcutaneous treatment for neuromyelitis optica spectrum disorder (NMOSD) (GlobeNewswire)
25.06.21	Roche’s Actemra/RoActemra receives U.S. FDA Emergency Use Authorization for the treatment of COVID-19 in hospitalised adults and children (GlobeNewswire)
24.06.21	FDA accepts application for Roche’s Port Delivery System with ranibizumab (PDS) for treatment of neovascular or “wet” age-related macular degeneration (nAMD) (GlobeNewswire)
15.06.21	Roche data at EAN 2021 showcase significant impact of therapies across diverse neuroscience portfolio (GlobeNewswire)
11.06.21	Roche announces data at EHA2021 reinforcing efficacy of Venclexta/Venclyxto combinations in chronic lymphocytic leukaemia and acute myeloid leukaemia (GlobeNewswire)
11.06.21	New Roche data for Evrysdi show improved motor function in pre-symptomatic babies after one year and confirm safety profile in previously treated people with spinal muscular atrophy (SMA) (GlobeNewswire)
08.06.21	Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal allowing for rapid self testing of COVID-19 at home (GlobeNewswire)
04.06.21	Roche presents latest advances with immunotherapies in non-Hodgkin lymphoma (GlobeNewswire)
25.05.21	European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Roche Hldg G	255.50	0.75 %	K V
Nestle	74.88	0.62 %	K V
CieFinRichemont	137.90	0.40 %	K V
Swiss Life Hldg	699.60	0.32 %	K V
Swisscom	504.50	0.30 %	K V
Sika	215.80	-0.37 %	K V
Givaudan	3’966.00	-0.40 %	K V
Lonza Grp	535.80	-0.41 %	K V
Geberit	514.60	-0.46 %	K V
ABB	49.07	-0.95 %	K V

mehr

16:02		Dow Jones 30 Industrial-Wert Merck-Aktie: So viel Gewinn hätte ein Merck-Investment von vor 3 Jahren eingefahren
16:02		S&P 500-Titel Pfizer-Aktie: So viel hätte eine Investition in Pfizer von vor 3 Jahren gekostet
16:00		Freundlicher Handel in New York: Zum Start des Dienstagshandels Pluszeichen im Dow Jones
15:57		Börse Europa: STOXX 50 mit positivem Vorzeichen
15:57		Pluszeichen in London: FTSE 100 am Nachmittag mit positivem Vorzeichen
12:25		LSE-Handel: Am Dienstagmittag Gewinne im FTSE 100
10:02		EURO STOXX 50-Wert Sanofi-Aktie: So viel Gewinn hätte eine Sanofi-Investition von vor 10 Jahren eingebracht